CN102861076B - Application of Houttuynoid A in antibacterial medicine - Google Patents
Application of Houttuynoid A in antibacterial medicine Download PDFInfo
- Publication number
- CN102861076B CN102861076B CN2012104186369A CN201210418636A CN102861076B CN 102861076 B CN102861076 B CN 102861076B CN 2012104186369 A CN2012104186369 A CN 2012104186369A CN 201210418636 A CN201210418636 A CN 201210418636A CN 102861076 B CN102861076 B CN 102861076B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- application
- preparation
- antibacterial
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FHNVKCJCSKWUFS-YLUJEXTNSA-N 4-[5,7-dihydroxy-4-oxo-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-yl]-7-hydroxy-2-nonyl-1-benzofuran-3-carbaldehyde Chemical compound C=12C(C=O)=C(CCCCCCCCC)OC2=C(O)C=CC=1C=1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FHNVKCJCSKWUFS-YLUJEXTNSA-N 0.000 title claims abstract description 50
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 201000007336 Cryptococcosis Diseases 0.000 abstract 1
- 241000221204 Cryptococcus neoformans Species 0.000 abstract 1
- 241000589540 Pseudomonas fluorescens Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to application of Houttuynoid A in preparation of an antibacterial medicine, belonging to the technical field of new application of medicine. Houttuynoid A has very strong effect on inhibiting escherichia coli, pseudomonas fluorescens, staphylococcus aureus, proteusbacillus vulgaris, cryptococcus neoformans, so that Houttuynoid A can be taken as the antibacterial medicine and is expected to be applied in the preparation of the relative medicines. The application of Houttuynoid A in preparation of the antibacterial medicineis disclosed firstly. The skeleton type belongs to new skeleton type, and the bacteriostasis activity of Houttuynoid A is unexpectedly strong; and the probability that other compounds provide any revelation does not exist, Houttuynoid A has the excellent substantive features, and Houttuynoid A obviously has a remarkable progress when being used for preventing and treating bacterial infection.
Description
Technical field
The present invention relates to the purposes of Houttuynoid A, relate in particular to the application of Houttuynoid A in the preparation anti-bacterial drug.
Background technology
the mankind's health and lives in the enhancing serious threat of the diffusion of pathogenic bacterium and drug resistance thereof, antibacterials are widely used in acquired immune deficiency syndrome (AIDS) as routine administration, organ transplantation and Chronic consumptions are (as cancer, diabetes, uremia etc.) treatment, although the antimicrobial agent of using clinically at present is (as ketoconazole, amikacin, gentamycin, voriconazole, itraconazole, terbinafine, amphotericin, fluconazol etc.) better to the curative effect of skin and superficial place infection, but the cumulative toxicity of these antibacterials is stronger, usually cause lesions of liver and kidney, digestive tract stimulates, dizzy, irritated etc., become one of focus of current medicament research and development so seek the novel antibacterial medicine of mechanism of action uniqueness.
the compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid A that the present invention relates in the preparation anti-bacterial drug, because framework types belongs to brand-new framework types, and it is active unexpectedly strong for bacteriostatic, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control that is used for simultaneously the antibacterial infection obviously has significant progress.
Summary of the invention
The object of the invention is to:
The application of a kind of Houttuynoid A of the present invention in the preparation anti-bacterial drug is provided.
Described compound H outtuynoid A structure is as shown in formula I:
Houttuynoid A has the effect of very strong inhibition escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, so Houttuynoid A can be used as the compound with antibacterial action, and be expected to be applied in the preparation antibacterials.
The purposes of Houttuynoid A in the preparation anti-bacterial drug belongs to open first, because framework types belongs to brand-new framework types, and it is active unexpectedly strong for bacteriostatic, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously the antibacterial infection obviously has significant progress.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams that prepare tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add the conventional adjuvant such as starch 180 grams that prepare capsule, mixing is encapsulatedly made 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: Houttuynoid A antibacterial activity
Antibacterial activity test is to adopt the method for concentration dilution, measures triplicate at every turn, and the test pathogen has escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, and bacterial concentration is 10
5Individual/mL.Houttuynoid A initial concentration is 50.0 μ g/mL(5% dimethyl sulfoxide DMSO), gradient dilution to 0.098 μ g/mL, the bacterium liquid of equivalent volumes and specimen Mixed culture are in 96 orifice plates, the antibacterial culturing temperature is respectively 37 ℃, observe after incubation time 24h, if discovery is the sample lowest concentration of antimicrobial when not having bacterium colony to form, i.e. the MIC value.This experiment positive control is amikacin sulfate, and Houttuynoid A the anti-bacterial result sees Table 1.
The antibiotic MIC value of table 1 Houttuynoid A (μ g/mL)
Conclusion: Houttuynoid A has very strong antibacterial activity, and therefore Houttuynoid A of the present invention is expected to be used to prepare the novel antibacterial medicine.
Claims (1)
1.Houttuynoid A is in the application of preparation in anti-bacterial drug, described antibacterial is escherichia coli, fluorescent pseudomonas, Staphylococcus aureus and Bacillus proteus, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104186369A CN102861076B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in antibacterial medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104186369A CN102861076B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in antibacterial medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861076A CN102861076A (en) | 2013-01-09 |
| CN102861076B true CN102861076B (en) | 2013-06-19 |
Family
ID=47440394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104186369A Active CN102861076B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in antibacterial medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861076B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103027907A (en) * | 2012-11-19 | 2013-04-10 | 何晓涛 | Application of Aphanamixoid A in preparation of antibacterial drugs |
-
2012
- 2012-10-27 CN CN2012104186369A patent/CN102861076B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103027907A (en) * | 2012-11-19 | 2013-04-10 | 何晓涛 | Application of Aphanamixoid A in preparation of antibacterial drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861076A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103251611A (en) | Application of Aspeverin in preparation of anti-bacteria medicines | |
| CN102861076B (en) | Application of Houttuynoid A in antibacterial medicine | |
| CN102872105B (en) | Application of Houttuynoid C in antibacterial medicine | |
| CN102872090B (en) | Application of Houttuynoid D in anti-bacterial agents | |
| CN103462968B (en) | Incarviatone A is preparing the application in anti-bacterial drug | |
| CN103446125B (en) | Lycojaponicumin B is preparing the application in anti-bacterial drug | |
| CN102895251A (en) | Application of Houttuynoid E in antibacterial drugs | |
| CN102872146A (en) | Application of Houttuynoid D in antibacterial drugs | |
| CN102872030B (en) | Application of Gypensapogenin B in antibacterial drugs | |
| CN103027907A (en) | Application of Aphanamixoid A in preparation of antibacterial drugs | |
| CN103446114A (en) | Applications of Sarcaboside A in antibacterial medicament | |
| CN102895238B (en) | Application of Gypensapogenin A in antibacterial medicament | |
| CN103381164B (en) | Chukrasone A is preparing the application in anti-bacterial drug | |
| CN103381153B (en) | Chukrasone B is preparing the application in anti-bacterial drug | |
| CN103638010B (en) | Application of Artoxanthochromane in antibacterial drugs | |
| CN103463037B (en) | Lycojaponicumin A is preparing the application in anti-bacterial drug | |
| CN103127067A (en) | Application of Eryngiolide A in antibacterial medicines | |
| CN103463075B (en) | Lycojaponicumin C is preparing the application in anti-bacterial drug | |
| CN103356517B (en) | Application of Scopariusins in preparation of antibacterial medicines | |
| CN102861087B (en) | Application of Houttuynoid D in anti-human fungi medicine | |
| CN103462982B (en) | Spirooliganones B is preparing the application in anti-bacterial drug | |
| CN103446106A (en) | Applications of Sarcaboside B in antibacterial medicament | |
| CN102861083B (en) | Application of Houttuynoid B in anti-human fungi medicine | |
| CN105287536A (en) | Application of castanospermine to preparation of antibacterial drugs | |
| CN105412091A (en) | Application of Daphnilongeranine C in preparing antibacterial drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU HANCHEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20130723 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226132 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130723 Address after: 226132, three Bridge Road, Yue Yue Industrial Zone, Haimen, Jiangsu, Nantong 188, China Patentee after: Jiangsu Hanchen Pharmaceutical Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG YUEYUE INDUSTRY CO., LTD. Free format text: FORMER OWNER: JIANGSU HANCHEN PHARMACEUTICAL CO., LTD. Effective date: 20150623 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150623 Address after: 226131 Jiangsu city of Nantong Province Haimen Yuelai town Fuxing Road, building 12, the town government compound Patentee after: Nantong Yue Yue Industrial Co., Ltd. Address before: 226132, three Bridge Road, Yue Yue Industrial Zone, Haimen, Jiangsu, Nantong 188, China Patentee before: Jiangsu Hanchen Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20181217 Address after: 226100 Fuxing Road, Yuet Lai Town, Haimen, Nantong, Jiangsu, 18 Patentee after: Haimen Zhi Zhou Industrial Design Co., Ltd. Address before: 226131 Government Courtyard, Building 12, Fuxing Road, Yuelai Town, Haimen City, Nantong City, Jiangsu Province Patentee before: Nantong Yue Yue Industrial Co., Ltd. |
|
| TR01 | Transfer of patent right |